部份中文波普瑞韋處方資料（僅供參考）
商品名稱: Victrelis
通用名稱: 波普瑞韋膠囊
英文名稱: boceprevir
漢語拼音: Bopuruiweijiaonang
適 應 症：
Victrelis是一種丙型肝炎病毒(HCV)NS*/4A蛋白酶抑製劑適用於與聚乙二醇干擾素α和利巴韋林【ribavirin】聯用基因型*感染慢性丙型肝炎CHC)的治療，在有代償性肝病(≥*8歲)成年患者，包括肝硬變，波普瑞韋說明書既往未治療或既往干擾素和利巴韋林治療已失敗患者。 VICTRELIS必須作為單藥治療使用。
用法用量：
800mg每天口服三次給藥(每*-*小時)與食物(一餐或小吃)。
(*)VICTRELIS必須與聚乙二醇干擾素α和利巴韋林聯用給藥。
(2)為特殊給藥指導參考聚乙二醇干擾素α和利巴韋林包裝插件。
不良反應：
在臨床試驗中接受VICTRELIS與PegIntron和REBETOL聯用成年受試者中最常報導的不良反應(大於**%受試者)是疲乏，波普瑞韋價格 貧血，噁心，頭痛和味覺障礙。
禁 忌：
(*)因為VICTRELIS必須與聚乙二醇干擾素α和利巴韋林給藥，也應用對聚乙二醇干擾素α和利巴韋林所有禁忌證。
(2)因為利巴韋林可能致出生缺陷和胎兒死亡，妊娠婦女中和女性伴侶妊娠男性禁忌boceprevir與聚乙二醇干擾素α和利巴韋林聯用。
(*)與高度依賴CYP*A4/*清除的藥物共同給藥，波普瑞韋規格 和因為升高血漿濃度伴隨嚴重和/或危及生命事件。
(4)強CYP*A4/*誘導劑wher顯著減低boceprevir血漿濃度可能伴隨減低療效。
注意事項
Victrelis與利巴韋林和聚乙二醇干擾素α使用：
(*)利巴韋林可能致出生缺陷和胎兒死亡：波普瑞韋膠囊多少錢在女性患者和男性患者的女性伴侶中避免妊娠。治療前患者必須有妊娠檢驗陰性；使用兩種或更多方式避孕，波普瑞韋療程 和每月妊娠檢驗。
(2)貧血 –Victrelis增添至聚乙二醇干擾素α和利巴韋林與單獨聚乙二醇干擾素α和利巴韋林比較是伴隨另外的血紅蛋白濃度減低。
(*)中性粒細胞減少 - Victrelis增添至聚乙二醇干擾素α和利巴韋林可能導致伴隨單獨聚乙二醇干擾素α和利巴韋林治療中性粒細胞減少惡化。
貯　藏
貯存在冰箱2-8°C(*6-46°F)直至發放。避免暴露於過熱。波普瑞韋哪裡賣 對使用患者，冰箱貯存Victrelis膠囊可保持穩定至標籤上失效期。 Victrelis也可貯存在室溫至2*°C(**°F) *個月。保持容器密閉。
生產企業
Merck Sharp & Dohme Ltd
Boceprevir: interaction with HIV protease inhibitors highlighted
The European Medicines Agency (EMA) has recommended that patients receiving concomitant therapy with the hepatitis C protease inhibitor boceprevir (Victrelis) and HIV protease inhibitors be reviewed for potential virologic rebound, following reports of a pharmacokinetic interaction.
Pharmacokinetic study
A study in 39 healthy volunteers showed that blood levels of three ritonavir-boosted protease inhibitors (darunavir, lopinavir and atazanavir) were markedly reduced when given with boceprevir. In addition, levels of boceprevir were reduced when given with ritonavir-boosted darunavir or lopinavir, although this effect was not seen with ritonavir–atazanavir.
Recommendations
The EMA states that co-administration of boceprevir with ritonavir-boosted darunavir or lopinavir is not recommended. Co-administration of atazanavir–ritonavir with boceprevir may be considered on a case-by-case basis in patients with suppressed HIV viral loads and without any suspected resistance to the HIV regimen. Increased clinical and laboratory monitoring is recommended in this situation.
Licensed indication
Victrelis is indicated for the treatment of chronic hepatitis C genotype 1, in combination with peginterferon alfa and ribavirin. The safety and efficacy of Victrelis in HIV co-infected patients has not been established.
https://www.medicines.org.uk/emc/print-document?documentId=24768